Human Granulocyte Colony-stimulating Factor Market

Human Granulocyte Colony-stimulating Factor Market contains market size and forecasts of Human Granulocyte Colony-stimulating Factor in global, including the following market information:

• Global Human Granulocyte Colony-stimulating Factor Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Human Granulocyte Colony-stimulating Factor Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Human Granulocyte Colony-stimulating Factor companies in 2021 (%)

The global Human Granulocyte Colony-stimulating Factor market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

300 g/Dose Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Human Granulocyte Colony-stimulating Factor include Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway, GenSci, SL PHARM, Kexing Bioproducts, Qilu Pharmaceutical, CSPC and Wuzhong Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Human Granulocyte Colony-stimulating Factor manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Human Granulocyte Colony-stimulating Factor Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Human Granulocyte Colony-stimulating Factor Market Segment Percentages, by Type, 2021 (%)

• 300 g/Dose
• 150 g/Dose
• 75 g/Dose
• Others

Global Human Granulocyte Colony-stimulating Factor Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Human Granulocyte Colony-stimulating Factor Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic

Global Human Granulocyte Colony-stimulating Factor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Human Granulocyte Colony-stimulating Factor Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Human Granulocyte Colony-stimulating Factor revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Human Granulocyte Colony-stimulating Factor revenues share in global market, 2021 (%)
• Key companies Human Granulocyte Colony-stimulating Factor sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Human Granulocyte Colony-stimulating Factor sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Chugai Pharmaceutical
• Kyowa Hakko Kirin
• Sanway
• GenSci
• SL PHARM
• Kexing Bioproducts
• Qilu Pharmaceutical
• CSPC
• Wuzhong Pharmaceutical
• Quangang Pharmaceutical
• Huabei Pharmaceutical
• Harbin Pharmaceutical
• Amoytop Biotech
• Jiuyuan Gene Engineering
• Four Rings Biopharmaceutical